{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:21:41Z","timestamp":1759335701534},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,23]]},"DOI":"10.7759\/cureus.65163","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T07:06:08Z","timestamp":1721718368000},"source":"Crossref","is-referenced-by-count":1,"title":["Secondary Adrenal Insufficiency as an Immune-Related Adverse Event of Pembrolizumab Therapy"],"prefix":"10.7759","author":[{"given":"Lorena","family":"Esca\u00f1o","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prarthana","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (Keytruda)","volume":"12","author":"Kwok G","year":"2016","unstructured":"Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Pembrolizumab (Keytruda). Hum Vaccin Immunother. 2016, 12:2777-89. 10.1080\/21645515.2016.1199310","journal-title":"Hum Vaccin Immunother"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar V","year":"2017","unstructured":"Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol. 2017, 8:49. 10.3389\/fphar.2017.00049","journal-title":"Front Pharmacol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-related adverse events associated with anti-PD-1\/PD-L1 treatment for malignancies: a meta-analysis","volume":"8","author":"Wang PF","year":"2017","unstructured":"Wang PF, Chen Y, Song SY, et al.. Immune-related adverse events associated with anti-PD-1\/PD-L1 treatment for malignancies: a meta-analysis. Front Pharmacol. 2017, 8:730. 10.3389\/fphar.2017.00730","journal-title":"Front Pharmacol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-020-01357-x","article-title":"Clinical characteristics of adrenal insufficiency as an immune-related adverse event in non-small-cell lung cancer","volume":"37","author":"Ida H","year":"2020","unstructured":"Ida H, Goto Y, Sato J, et al.. Clinical characteristics of adrenal insufficiency as an immune-related adverse event in non-small-cell lung cancer. Med Oncol. 2020, 37:30. 10.1007\/s12032-020-01357-x","journal-title":"Med Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.11814","article-title":"Adrenal insufficiency related to anti-programmed death-1 therapy","volume":"37","author":"Ariyasu R","year":"2017","unstructured":"Ariyasu R, Horiike A, Yoshizawa T, et al.. Adrenal insufficiency related to anti-programmed death-1 therapy. Anticancer Res. 2017, 37:4229-32. 10.21873\/anticanres.11814","journal-title":"Anticancer Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.41049","article-title":"Pembrolizumab-induced adrenal insufficiency presenting eight months after cessation of treatment","volume":"15","author":"Zilberman S","year":"2023","unstructured":"Zilberman S, Rafii DC, Giunta J. Pembrolizumab-induced adrenal insufficiency presenting eight months after cessation of treatment. Cureus. 2023, 15:e41049. 10.7759\/cureus.41049","journal-title":"Cureus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa R","year":"2018","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018, 4:173-82. 10.1001\/jamaoncol.2017.3064","journal-title":"JAMA Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1210\/js.2017-00170","article-title":"Polyendocrinopathy resulting from pembrolizumab in a patient with a malignant melanoma","volume":"1","author":"Paepegaey AC","year":"2017","unstructured":"Paepegaey AC, Lheure C, Ratour C, et al.. Polyendocrinopathy resulting from pembrolizumab in a patient with a malignant melanoma. J Endocr Soc. 2017, 1:646-9. 10.1210\/js.2017-00170","journal-title":"J Endocr Soc"},{"key":"ref9","article-title":"The Adrenal Cortex - Chapter 13","author":"Melmed S","year":"2020","unstructured":"Melmed S, Auchus RJ, Goldfine AB, et al.. The Adrenal Cortex - Chapter 13. Williams Textbook of Endocrinology 15th edition. Elsevier, Philadelphia, PA; 2020. 514-5."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1159\/000519597","article-title":"Pembrolizumab-induced adrenal insufficiency in patients with untreated advanced non-small cell lung cancer: a case series","volume":"14","author":"Sonehara K","year":"2021","unstructured":"Sonehara K, Tateishi K, Araki T, Komatsu M, Akahane J, Yamamoto H, Hanaoka M. Pembrolizumab-induced adrenal insufficiency in patients with untreated advanced non-small cell lung cancer: a case series. Case Rep Oncol. 2021, 14:1561-6. 10.1159\/000519597","journal-title":"Case Rep Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13101812","article-title":"Adrenal failure: an evidence-based diagnostic approach","volume":"13","author":"Shaikh S","year":"2023","unstructured":"Shaikh S, Nagendra L, Shaikh S, Pappachan JM. Adrenal failure: an evidence-based diagnostic approach. Diagnostics (Basel). 2023, 13:1812. 10.3390\/diagnostics13101812","journal-title":"Diagnostics (Basel)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/275795-secondary-adrenal-insufficiency-as-an-immune-related-adverse-event-of-pembrolizumab-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T07:06:12Z","timestamp":1721718372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/275795-secondary-adrenal-insufficiency-as-an-immune-related-adverse-event-of-pembrolizumab-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.65163","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,23]]}}}